Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
»
Companies
» Company Monitoring Page for BeiGene
Company Monitoring Page for BeiGene
latest headlines for company on cafepharma
[podcast]Brukinsa approval raises BeiGene’s hematology profile
Medical Marketing and Media
Wed, 03/20/24 - 09:38 pm
Tags:
BeiGene
,
Brukinsa
,
FDA
,
hematology
FDA approves expanded use of BeiGene's blood cancer drug
Reuters
Thu, 03/7/24 - 05:30 pm
Tags:
BeiGene
,
FDA
,
Brukinsa
,
Gazyva
BeiGene Inks Potential $1.3B Deal with Ensem for Early-Stage CDK2 Inhibitor
BioSpace
Tue, 11/21/23 - 11:54 am
Tags:
BeiGene
,
Ensem
,
EXT-197
,
cancer
BeiGene to go solo with cancer drug after Novartis deal termination
Yahoo/Reuters
Tue, 09/19/23 - 10:30 am
Tags:
BeiGene
,
Novartis
,
cancer
,
tislelizumab
,
Tivimbra
Bristol Myers, BeiGene end legacy Celgene deal with settlement years after China ban
Fierce Pharma
Thu, 08/3/23 - 11:22 am
Tags:
Bristol Myers Squibb
,
BeiGene
,
Celgene
Novartis retreats from TIGIT, handing $300M candidate back to BeiGene
Fierce Biotech
Tue, 07/11/23 - 10:22 am
Tags:
Novartis
,
anti-TIGIT
,
BeiGene
AbbVie's Imbruvica-Brukinsa patent suit may have merit, and BeiGene will likely settle: expert
Fierce Pharma
Tue, 06/27/23 - 10:21 pm
Tags:
AbbVie
,
patents
,
BeiGene
,
legal
,
Btk inhibitors
AbbVie sues BeiGene over brand-new Imbruvica patent as blood cancer rivalry heats up
Fierce Pharma
Fri, 06/16/23 - 09:44 am
Tags:
AbbVie
,
Pharmacyclics
,
BeiGene
,
Brukinsa
,
patents
,
Imbruvica
,
blood cancer
BeiGene's gastric cancer drug succeeds in late-stage trial
Reuters
Thu, 04/20/23 - 11:41 am
Tags:
BeiGene
,
gastric cancer
,
clinical trials
,
tislelizumab
BeiGene Enters New Phase to Expand US Manufacturing and R&D Footprint
NJ Business
Wed, 03/22/23 - 11:12 am
Tags:
BeiGene
,
New Jersey
,
R&D
,
drug manufacturing
BeiGene pulls out of Leap of faith, letting option on immuno-oncology candidate lapse
Fierce Biotech
Fri, 03/17/23 - 09:55 am
Tags:
BeiGene
,
immuno-oncology
,
Leap Therapeutics
,
DKN-01
Big Pharma regained ‘mojo’ last year, but biotech valuations remain ‘precarious’: report
Fierce Biotech
Sun, 03/5/23 - 03:06 pm
Tags:
Big Pharma
,
Novo Nordisk
,
Moderna Therapeutics
,
Gilead Sciences
,
BeiGene
BeiGene doubles sales as Brukinsa, tislelizumab gear up for key launches
Fierce Pharma
Mon, 02/27/23 - 07:06 pm
Tags:
BeiGene
,
Brukinsa
,
earnings
,
tislelizumab
This Week at FDA: Pallone pushes for greater ClinicalTrials.gov enforcement, FDA rejects Eli Lilly Alzheimer’s drug, and more
RAPS.org
Sun, 01/22/23 - 01:00 pm
Tags:
FDA
,
regulatory
,
clinical trials
,
clinicaltrials.gov
,
Eli Lilly
,
donanemab
,
Medtronic
,
BeiGene
,
Seagen
BeiGene's Brukinsa wins CLL approval after topping Imbruvica in head-to-head trial
Endpoints
Thu, 01/19/23 - 08:55 pm
Tags:
BeiGene
,
Brukinsa
,
CLL
,
FDA
,
Imbruvica
Big caps bounce back for biopharma
EP Vantage
Mon, 01/16/23 - 11:14 am
Tags:
pharma stocks
,
Amgen
,
BeiGene
,
Bristol Myers Squibb
,
Gilead Sciences
,
Lantheus Holdings
,
Madrigal Pharmaceuticals
,
Merck
,
Moderna Therapeutics
,
Novo Nordisk
,
Prometheus Biosciences
,
Roche
ASH 2022 – pirtobrutinib leads the post-Imbruvica charge
EP Vantage
Wed, 12/14/22 - 10:18 am
Tags:
ASH 2022
,
Eli Lilly
,
BeiGene
,
Nurix Therapeutics
,
Brukinsa
,
pirtobrutinib
,
NX-2127
Go or no go? Mirati heads to the FDA
EP Vantage
Wed, 11/30/22 - 10:34 am
Tags:
FDA
,
Mirati Therapeutics
,
Gilead Sciences
,
Coherus Biosciences
,
Roche
,
Biogen
,
TG Therapeutics
,
Ipsen
,
Novartis
,
BeiGene
,
Cytokinetics
Few safe havens surface in another down quarter for biopharma
EP Vantage
Fri, 10/14/22 - 10:03 am
Tags:
biopharma stocks
,
COVID-19
,
Eli Lilly
,
Bristol Myers Squibb
,
Merck
,
Daiichi Sankyo
,
Vertex Pharmaceuticals
,
Takeda
,
Neurocrine
,
Sarepta Therapeutics
,
Orion
,
Pfizer
,
GSK
,
Roche
,
Moderna Therapeutics
,
BeiGene
,
BioNTech
,
Novavax
,
CureVac
BeiGene heaps more pressure on AbbVie, J&J with new Brukinsa head-to-head win over Imbruvica
Fierce Pharma
Wed, 10/12/22 - 11:00 am
Tags:
BeiGene
,
AbbVie
,
JNJ
,
Imbruvica
,
blood cancers
,
Brukinsa
Pages
1
2
3
4
5
next ›
last »
last 30 twitter posts
current feelings about your job
job rating
*
1 - I hate my job
2
3
4
5
6
7 - I love my job
Please rate how you feel about your job this moment. 1 = "I hate my job" and 7 = "I love my job"
please tell us why
*
your industry
*
your job title (optional)
your company
*
published
N/A
published
not published
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
an umbrella protects you from: rain, sand, hunger
*
Fill in the blank.